Download PDF
Semin Musculoskelet Radiol 2007; 11(3): 215-230
DOI: 10.1055/s-2008-1038311
Published by Thieme Medical Publishers

Genetics for the Diagnosis and Treatment of Mesenchymal Tumors

Jerzy Lasota1 , Julie C. Fanburg-Smith1
  • 1Department of Soft Tissue and Orthopedic Pathology, Armed Forces Institute of Pathology, Washington, D.C.
Further Information

Publication History

Publication Date:
07 February 2008 (online)

Also available at
    Permissions and Reprints

ABSTRACT

Cytogenetics and molecular genetics play an important role in the diagnosis of soft tissue and bone mesenchymal tumors. This update focuses on cytogenetic and molecular genetic techniques commonly used for evaluation of mesenchymal tumors, including karyotyping, fluorescent in situ hybridization, and polymerase chain reaction. Examples of different techniques, inherent technical problems, and interpretation of the results are discussed. Additionally, limitations related to the type of material available for genotyping (fresh, frozen, or formalin-fixed paraffin-embedded tissue) are covered. Cytogenetic and molecular genetic alterations identified in various mesenchymal tumors are often valuable for diagnosis, prognosis, and treatment strategies.

KEYWORDS

Sarcoma - genetics - karyotyping - FISH - PCR

REFERENCES

  • 1 Cooper G M. Oncogenes. 2nd ed. Boston; Jones and Bartlett Publishers International 1995
    Google Scholar
  • 2 Petit M M, Swarts S, Bridge J A et al.. Expression of reciprocal fusion transcripts of the HMGIC and LPP genes in parosteal lipoma.  Cancer Genet Cytogenet. 1998;  106 18-23
    CrossrefPubMedGoogle Scholar
  • 3 Rogalla P, Kazimierczak B, Meyer-Bolte K et al.. The t(3;12)(q27;q14-q15) with underlying HMGIC-LPP fusion is not determining an adipocytic phenotype.  Genes Chromosomes Cancer. 1998;  22 100-104
    CrossrefPubMedGoogle Scholar
  • 4 Petit M M, Mols R, Schoenmakers E F et al.. LPP, the preferred fusion partner gene of HMGIC in lipomas, is a novel member of the LIM protein gene family.  Genomics. 1996;  36 118-129
    CrossrefPubMedGoogle Scholar
  • 5 Petit M M, Schoenmakers E F, Huysmans C et al.. LHFP, a novel translocation partner gene of HMGIC in a lipoma, is a member of a new family of LHFP-like genes.  Genomics. 1999;  57 438-441
    CrossrefPubMedGoogle Scholar
  • 6 Broberg K, Zhang M, Strombeck B et al.. Fusion of RDC1 with HMGA2 in lipomas as the result of chromosome aberrations involving 2q35-37and 12q13-15.  Int J Oncol. 2002;  21 321-326
    PubMedGoogle Scholar
  • 7 Kazmierczak B, Dal Cin P, Wanschura S et al.. Cloning and molecular characterization of part of a new gene fused to HMGIC in mesenchymal tumors.  Am J Pathol. 1998;  152 431-435
    PubMedGoogle Scholar
  • 8 Ballaux F, Debiec-Rychter M, De Wever I et al.. Chondroid lipoma is characterized by t(11;16)(q13;p12-13).  Virchows Arch. 2004;  444 208-210
    CrossrefPubMedGoogle Scholar
  • 9 Sandberg A A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: lipoma.  Cancer Genet Cytogenet. 2004;  150 93-115
    CrossrefPubMedGoogle Scholar
  • 10 Meloni A M, Spanier S S, Bush C H et al.. Involvement of 10q22 and 11q13 in hibernoma.  Cancer Genet Cytogenet. 1994;  72 59-64
    CrossrefPubMedGoogle Scholar
  • 11 Mertens F, Rydholm A, Brosjö O et al.. Hibernomas are characterized by rearrangements of chromosome bands 11q13-21.  Int J Cancer. 1994;  58 503-505
    CrossrefPubMedGoogle Scholar
  • 12 Mrózek K, Karakousis C P, Bloomfield C D. Band 11q13 in nonrandomly rearranged in hibernomas.  Genes Chromosomes Cancer. 1994;  9 145-147
    CrossrefPubMedGoogle Scholar
  • 13 Gisselsson D, Höglund M, Mertens F et al.. Hibernomas are characterized by homozygous deletions in the multiple endocrine neoplasia type I region. Metaphase fluorescence in situ hybridization reveals complex rearrangements not detected by conventional cytogenetics.  Am J Pathol. 1999;  155 61-66
    PubMedGoogle Scholar
  • 14 Maire G, Forus A, Foa C et al.. 11q13 alterations in two cases of hibernoma: large heterozygous deletions and rearrangement breakpoints near GARP in 11q13.5  Genes Chromosomes Cancer. 2003;  37 389-395
    CrossrefPubMedGoogle Scholar
  • 15 Turaga K K, Silva-Lopez E, Sanger W G et al.. A (9;11)(q34;q13) translocation in hibernoma.  Cancer Genet Cytogenet. 2006;  170 163-166
    CrossrefPubMedGoogle Scholar
  • 16 Astrom A, D'Amore E S, Sainati L et al.. Evidence of involvement of the PLAG1 gene in lipoblastomas.  Int J Oncol. 2000;  16 1107-1110
    PubMedGoogle Scholar
  • 17 Hibbard M K, Kozakewich H P, Dal Cin P et al.. PLAG1 fusion oncogenes in lipoblastoma.  Cancer Res. 2000;  60 4869-4872
    PubMedGoogle Scholar
  • 18 Gisselsson D, Hibbard M K, Dal Cin P et al.. PLAG1 alterations in lipoblastoma: involvement in varied mesenchymal cell types and evidence for alternative oncogenic mechanisms.  Am J Pathol. 2001;  159 955-962
    PubMedGoogle Scholar
  • 19 Sciot R, De Wever I, Debiec-Rychter M. Lipoblastoma in a 23-year-old male: distinction from atypical lipomatous tumor using cytogenetic and fluorescence in-situ hybridization analysis.  Virchows Arch. 2003;  442 468-471
    PubMedGoogle Scholar
  • 20 Schoenmakers E F, Huysmans C, van de Ven W J. Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12;14) uterine leiomyomas.  Cancer Res. 1999;  59 19-23
    PubMedGoogle Scholar
  • 21 Moore S D, Herrick S R, Ince T A et al.. Uterine leiomyomata with t(10;17) disrupt the histone acetyltransferase MORF.  Cancer Res. 2004;  64 5570-5577
    CrossrefPubMedGoogle Scholar
  • 22 Kurose K, Mine N, Doi D et al.. Novel gene fusion COX6C at 8q22-23 to HMGIC at 12q15 in a uterine leiomyoma.  Genes Chromosomes Cancer. 2000;  27 303-307
    CrossrefPubMedGoogle Scholar
  • 23 Mine N, Kurose K, Konishi H et al.. Fusion of a sequence from HEI10 (14q11) to the HMGIC gene at 12q15 in a uterine leiomyoma.  Jpn J Cancer Res. 2001;  92 135-139
    PubMedGoogle Scholar
  • 24 Kazmierczak B, Hennig Y, Wanschura S et al.. Description of a novel fusion transcript between HMGI-C, a gene encoding for a member of the high mobility group proteins, and the mitochondrial aldehyde dehydrogenase gene.  Cancer Res. 1995;  55 6038-6039
    PubMedGoogle Scholar
  • 25 Kazmierczak B, Pohnke Y, Bullerdiek J. Fusion transcripts between HMGIC gene and RTVL-H-related sequences in mesenchymal tumors without cytogenetic aberrations.  Genomics. 1996;  38 223-226
    CrossrefPubMedGoogle Scholar
  • 26 Nucci M R, Weremowicz S, Neskey D M et al.. Chromosomal translocation t(8;12) induces aberrant HMGIC expression in aggressive angiomyxoma of the vulva.  Genes Chromosomes Cancer. 2001;  32 172-176
    CrossrefPubMedGoogle Scholar
  • 27 Micci F, Panagopoulos I, Bjerkehagen B et al.. Deregulation of HMGA2 in an aggressive angiomyxoma with t(11;12)(q23;q15).  Virchows Arch. 2006;  448 838-842
    CrossrefPubMedGoogle Scholar
  • 28 Rabban J T, Dal Cin P, Oliva E. HMGA2 rearrangement in a case of vulvar aggressive angiomyxoma.  J Gynecol Pathol. 2006;  25 403-407
    PubMedGoogle Scholar
  • 29 Tallini G, Dorfman H, Brys P et al.. Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours: a report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group.  J Pathol. 2002;  196 194-203
    CrossrefPubMedGoogle Scholar
  • 30 Dahlen A, Mertens F, Rydholm A et al.. Fusion, disruption, and expression of HMGA2 in bone and soft tissue chondromas.  Mod Pathol. 2003;  16 1132-1140
    CrossrefPubMedGoogle Scholar
  • 31 Rogalla P, Lemke I, Kazmierczak B et al.. An identical HMGIC-LPP fusion transcript is consistently expressed in pulmonary chondroid hamartomas with t(3;12)(q27-28;q14-15).  Genes Chromosomes Cancer. 2000;  29 363-366
    CrossrefPubMedGoogle Scholar
  • 32 Blank C, Schoenmakers E F, Rogalla P et al.. Intragenic breakpoint within RAD51L1 in a t(6;14)(p21.3;q24) of a pulmonary chondroid hamartoma.  Cytogenet Cell Genet. 2001;  95 17-19
    CrossrefPubMedGoogle Scholar
  • 33 Lemke I, Rogalla P, Bullerdiek J. A novel LPP fusion gene indicates the crucial role of truncated LPP proteins in lipomas and pulmonary chondroid hamartomas.  Cytogenet Cell Genet. 2001;  95 153-156
    CrossrefPubMedGoogle Scholar
  • 34 Lemke I, Rogalla P, Grundmann F et al.. Expression of the HMGA2-LPP fusion transcript in only 1 of 61 karyotypically normal pulmonary chondroid hamartomas.  Cancer Genet Cytogenet. 2002;  138 160-164
    CrossrefPubMedGoogle Scholar
  • 35 Von Ahsen I, Rogalla P, Bullerdiek J. Expression patterns of the LPP-HMGA2 fusion transcript in pulmonary chondroid hamartomas with t(13;12)(q27 approximately 28;q14 approximately 15).  Cancer Genet Cytogenet. 2005;  163 68-70
    CrossrefPubMedGoogle Scholar
  • 36 Halbert A R, Harrison W R, Hicks M J et al.. Cytogenetic analysis of a scapular chondromyxoid fibroma.  Cancer Genet Cytogenet. 1998;  104 52-56
    CrossrefPubMedGoogle Scholar
  • 37 Granter S R, Renshaw A A, Kozakewich H P et al.. The pericentromeric inversion, inv (6)(p25q13), is a novel diagnostic marker in chondromyxoid fibroma.  Mod Pathol. 1998;  11 1071-1074
    PubMedGoogle Scholar
  • 38 Safar A, Nelson M, Neff J R et al.. Recurrent anomalies of 6q25 in chondromyxoid fibroma.  Hum Pathol. 2000;  31 306-311
    CrossrefPubMedGoogle Scholar
  • 39 Smith C A, Magenis R E, Himoe E et al.. Chondromyxoid fibroma of the nasal cavity with an interstitial insertion between chromosomes 6 and 19.  Cancer Genet Cytogenet. 2006;  171 97-100
    CrossrefPubMedGoogle Scholar
  • 40 Baruffi M R, Volpon J B, Neto J B et al.. Osteoid osteomas with chromosome alterations involving 22q.  Cancer Genet Cytogenet. 2001;  124 127-131
    CrossrefPubMedGoogle Scholar
  • 41 Nilsson M, Domanski H A, Mertens F et al.. Molecular cytogenetic characterization of recurrent translocation breakpoints in bizarre parosteal osteochondromatous proliferation (Nora's lesion).  Hum Pathol. 2004;  35 1063-1069
    CrossrefPubMedGoogle Scholar
  • 42 Endo M, Hasegawa T, Tashiro T et al.. Bizarre parosteal osteochondromatous proliferation with a t(1;17) translocation.  Virchows Arch. 2005;  447 99-102
    CrossrefPubMedGoogle Scholar
  • 43 Storlazzi C T, Wozniak A, Panagopoulos I et al.. Rearrangement of the COL12A1 and COL4A5 genes in subungual exostosis: molecular cytogenetic delineation of the tumor-specific translocation t(X;6)(q13-14,q22).  Int J Cancer. 2006;  118 1972-1976
    CrossrefPubMedGoogle Scholar
  • 44 Oliveira A M, Perez-Atayde A R, Inwards C Y et al.. USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts.  Am J Pathol. 2004;  165 1773-1780
    CrossrefPubMedGoogle Scholar
  • 45 Oliveira A M, His B L, Weremowicz S et al.. USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst.  Cancer Res. 2004;  64 1920-1923
    CrossrefPubMedGoogle Scholar
  • 46 Oliveira A M, Perez-Atayde A R, Dal Cin P et al.. Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes.  Oncogene. 2005;  24 3419-3426
    CrossrefPubMedGoogle Scholar
  • 47 West R B, Rubin B P, Miller M A et al.. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells.  Proc Natl Acad Sci U S A. 2006;  103 690-695
    CrossrefPubMedGoogle Scholar
  • 48 Cupp J S, Miller M A, Montgomery K D et al.. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and reactive synovitides.  Am J Surg Pathol. 2007;  31 970-976
    PubMedGoogle Scholar
  • 49 Möller E, Mandahl N, Mertens F et al.. Molecular identification of COL6A3-CSF1 fusion transcripts in tenosynovial giant cell tumors.  Genes Chromosomes Cancer. 2008;  47(1) 21-25 , Epub
    CrossrefPubMedGoogle Scholar
  • 50 Waters B L, Panagopoulos I, Allen E F. Genetic characterization of angiomatoid fibrous histiocytoma identifies fusion of the FUS and ATF-1 genes induced by a chromosomal translocation involving bands 12q13 and 16p11.  Cancer Genet Cytogenet. 2000;  121 109-116
    CrossrefPubMedGoogle Scholar
  • 51 Raddaoui E, Donner L R, Panagopoulos I et al.. Fusion of the FUS and ATF1 genes in a large deep-seated angiomatoid fibrous histiocytoma.  Diagn Mol Pathol. 2002;  11 157-162
    CrossrefPubMedGoogle Scholar
  • 52 Antonescu C R, Dal Cin P, Nafa K et al.. EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma.  Genes Chromosomes Cancer. 2007;  46 1051-1060
    CrossrefPubMedGoogle Scholar
  • 53 Hallor K H, Micci F, Meis-Kindblom J M et al.. Fusion genes in angiomatoid fibrous histiocytoma.  Cancer Lett. 2007;  251 158-163
    CrossrefPubMedGoogle Scholar
  • 54 Pedeutour F, Simon M P, Minoletti F et al.. Ring 22 chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers of chromosome 17 and 22 sequences.  Cancer Res. 1995;  55 2400-2403
    PubMedGoogle Scholar
  • 55 Pedeutour F, Simon M P, Minoletti F et al.. Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement.  Cytogenet Cell Genet. 1996;  72 171-174
    PubMedGoogle Scholar
  • 56 Kiuru-Kuhlefelt S, El-Rifai W, Fanburg-Smith J et al.. Concomitant DNA copy number amplification at 17q and 22q in dermatofibrosarcoma protuberans.  Cytogenet Cell Genet. 2001;  92 192-195
    CrossrefPubMedGoogle Scholar
  • 57 Simon M P, Pedeutour F, Sirvent N et al.. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma.  Nat Genet. 1997;  15 95-98
    PubMedGoogle Scholar
  • 58 Shimizu A, O'Brien K P, Sjoblom T et al.. The dermatofibrosarcoma protuberans-associated collagen type Iα1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB.  Cancer Res. 1999;  59 3719-3723
    PubMedGoogle Scholar
  • 59 Simon M P, Navarro M, Roux D et al.. Structural and functional analysis of a chimeric protein COL1A1-PDGFB generated by the translocation t(17;22)(q22;q13.1) in dermatofibrosarcoma protuberans (DP).  Oncogene. 2001;  20 2965-2975
    CrossrefPubMedGoogle Scholar
  • 60 O'Brien K P, Seroussi E, Dal Cin P et al.. Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas protuberans and giant cell fibroblastomas.  Genes Chromosomes Cancer. 1998;  23 187-193
    CrossrefPubMedGoogle Scholar
  • 61 Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment.  Genes Chromosomes Cancer. 2003;  37 1-19
    CrossrefPubMedGoogle Scholar
  • 62 Sandberg A A, Bridge J A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: dermatofibrosarcoma protuberans and giant cell fibroblastoma.  Cancer Genet Cytogenet. 2003;  140 1-12
    CrossrefPubMedGoogle Scholar
  • 63 Nakanishi G, Lin S N, Asagoe K et al.. A novel fusion gene of collagen type I alpha 1 (exon 31) and platelet-derived growth factor B-chain (exon 2) in dermatofibrosarcoma protuberans.  Eur J Dermatol. 2007;  17 217-219
    PubMedGoogle Scholar
  • 64 Storlazzi C T, Mertens F, Nascimento A et al.. Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma.  Hum Mol Genet. 2003;  12 2349-2358
    CrossrefPubMedGoogle Scholar
  • 65 Reid R, de Silva M V, Paterson L et al.. Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes share a common t(7;16)(q34;p11).  Am J Surg Pathol. 2003;  27 1229-1236
    CrossrefPubMedGoogle Scholar
  • 66 Panagopoulos I, Storlazzi C T, Fletcher C D et al.. The chimeric FUS/CREB312 gene is specific for low-grade fibromyxoid sarcoma.  Genes Chromosomes Cancer. 2004;  40 218-228
    CrossrefPubMedGoogle Scholar
  • 67 Mertens F, Fletcher C D, Antonescu C R et al.. Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene.  Lab Invest. 2005;  85 408-415
    CrossrefPubMedGoogle Scholar
  • 68 Guillou L, Benhattar J, Gengler C et al.. Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group.  Am J Surg Pathol. 2007;  31 1387-1402
    PubMedGoogle Scholar
  • 69 Knezevich S R, McFadden D E, Tao W et al.. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.  Nat Genet. 1998;  18 184-187
    PubMedGoogle Scholar
  • 70 Knezevich S R, Garnett M J, Pysher T J et al.. ETV6-NTRK3 gene fusion and trisomy 11 established a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma.  Cancer Res. 1998;  58 5046-5048
    PubMedGoogle Scholar
  • 71 Rubin B P, Chen C J, Morgan T W et al.. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma.  Am J Pathol. 1998;  153 1451-1458
    PubMedGoogle Scholar
  • 72 Lawrence B, Perez-Atayde A, Hibbard M K et al.. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.  Am J Pathol. 2000;  157 377-384
    CrossrefPubMedGoogle Scholar
  • 73 Bridge J A, Kanamori M, Ma Z et al.. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor.  Am J Pathol. 2001;  159 411-415
    PubMedGoogle Scholar
  • 74 Ma Z, Hill D A, Collins M H et al.. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor.  Genes Chromosomes Cancer. 2003;  37 98-105
    CrossrefPubMedGoogle Scholar
  • 75 Cools J, Wlodarska I, Somers R et al.. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.  Genes Chromosomes Cancer. 2002;  34 354-362
    CrossrefPubMedGoogle Scholar
  • 76 Debelenko L V, Arthur D C, Pack S D et al.. Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor.  Lab Invest. 2003;  83 1255-1265
    CrossrefPubMedGoogle Scholar
  • 77 Debiec-Rychter M, Marynen P, Hagenmeijer A et al.. ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor.  Genes Chromosomes Cancer. 2003;  38 187-190
    CrossrefPubMedGoogle Scholar
  • 78 Panagopoulos I, Nilsson T, Domanski H A et al.. Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor.  Int J Cancer. 2006;  118 1181-1186
    CrossrefPubMedGoogle Scholar
  • 79 Mendlick M R, Nelson M, Pickering D et al.. Translocation t(1;3)(p36.3q25) is a nonrandom aberration in epithelioid hemangioendothelioma.  Am J Surg Pathol. 2001;  25 684-687
    CrossrefPubMedGoogle Scholar
  • 80 He M, Das K, Blacksin M et al.. A translocation involving the placental growth factor gene is identified in an hemangioendothelioma.  Cancer Genet Cytogenet. 2006;  168 150-154
    CrossrefPubMedGoogle Scholar
  • 81 Koontz J I, Soreng A L, Nucci M et al.. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors.  Proc Natl Acad Sci U S A. 2001;  98 6348-6353
    CrossrefPubMedGoogle Scholar
  • 82 Micci F, Panagopoulos I, Bjerkehagen B et al.. Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial stromal sarcomas.  Cancer Res. 2006;  66 107-112
    CrossrefPubMedGoogle Scholar
  • 83 Henn W, Wullich B, Thonnes M et al.. Recurrent t(12;19)(q13;q13.3) in intracranial and extracranial hemangiopericytoma.  Cancer Genet Cytogenet. 1993;  71 151-154
    CrossrefPubMedGoogle Scholar
  • 84 Clark J, Benjamin H, Gill S et al.. Fusion of the EWS gene to CHN, a member of the steroid/thyroid receptor gene superfamily, in a human myxoid chondrosarcoma.  Oncogene. 1996;  12 229-235
    PubMedGoogle Scholar
  • 85 Labelle Y, Zucman J, Stenman G et al.. Oncogenic conversion of the novel orphan nuclear receptor by chromosome translocation.  Hum Mol Genet. 1995;  4 2219-2226
    CrossrefPubMedGoogle Scholar
  • 86 Attwooll C, Tariq M, Harris M et al.. Identification of a novel fusion gene involving hTAFII68 and CHN from a t(9;17)(q22;q11.2) translocation in an extraskeletal myxoid chondrosarcoma.  Oncogene. 1999;  18 7599-7601
    CrossrefPubMedGoogle Scholar
  • 87 Sjögren H, Meis-Kindblom J, Kindblom L G et al.. Fusion of the EWS-related gene TAF2N to TEC in extraskeletal myxoid chondrosarcoma.  Cancer Res. 1999;  59 5064-5067
    PubMedGoogle Scholar
  • 88 Sjögren H, Wedell B, Kindblom J M et al.. Fusion of the basic helix-loop-helix protein TCF12 to TEC in extraskeletal myxoid chondrosarcoma with translocation t(9;15)(q22;q21).  Cancer Res. 2000;  60 6832-6835
    PubMedGoogle Scholar
  • 89 Panagopoulos I, Mencinger M, Dietrich C U et al.. Fusion of the RBP56 and CHN genes in extraskeletal myxoid chondrosarcomas with translocation t(9;17)(q22;q11).  Oncogene. 1999;  18 7594-7598
    CrossrefPubMedGoogle Scholar
  • 90 Aurias A, Rimbout C, Buffe D et al.. Translocation involving chromosome 22 in Ewing's sarcoma: a cytogenetic study of four fresh tumors.  Cancer Genet Cytogenet. 1984;  12 21-25
    CrossrefPubMedGoogle Scholar
  • 91 Turc-Carel C, Philip I, Berger M-P et al.. Chromosomal translocations 11;22 in cell lines of Ewing's sarcoma.  C R Seances Acad Sci III. 1983;  296 1101-1103
    PubMedGoogle Scholar
  • 92 Whang-Peng J, Triche T J, Knutsen T et al.. Chromosome translocation in peripheral neuroepithelioma.  N Engl J Med. 1984;  311 584-585
    PubMedGoogle Scholar
  • 93 Whang-Peng J, Triche T J, Knutsen T et al.. Cytogenetic characterization of selected small round cell tumors of childhood.  Cancer Genet Cytogenet. 1986;  21 185-208
    CrossrefPubMedGoogle Scholar
  • 94 Delattre O, Zucman J, Plougastel B et al.. Gene fusion with an ETS DNA binding domain caused by chromosome translocation in human tumors.  Nature. 1992;  359 162-165
    CrossrefPubMedGoogle Scholar
  • 95 Zucman J, Delattre O, Desmaze C et al.. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints.  Genes Chromosomes Cancer. 1992;  5 271-277
    CrossrefPubMedGoogle Scholar
  • 96 Zucman J, Melot T, Desmaze C et al.. Combinatorial generation of variable fusion proteins in Ewing family of tumors.  EMBO J. 1993;  12 4481-4487
    PubMedGoogle Scholar
  • 97 Sorensen P H, Lessnick S L, Lopez-Terrada D et al.. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG.  Nat Genet. 1994;  6 146-151
    PubMedGoogle Scholar
  • 98 Jeon I S, Davis J N, Braun B S et al.. A variant Ewing's sarcoma translocation t(7;22) fuses the EWS gene to the ETS gene ETV1.  Oncogene. 1995;  10 1229-1234
    PubMedGoogle Scholar
  • 99 Kaneko Y, Yoshida K, Handa M et al.. Fusion of an ETS-family gene, EIAF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy.  Genes Chromosomes Cancer. 1996;  15 115-121
    CrossrefPubMedGoogle Scholar
  • 100 Peter M, Couturier J, Pacquement H et al.. A new member of the ETS family fused to EWS in Ewing tumors.  Oncogene. 1997;  14 1159-1164
    CrossrefPubMedGoogle Scholar
  • 101 Mastrangelo T, Modena P, Tornielli S et al.. A novel zinc finger gene is fused to EWS in small round cell tumor.  Oncogene. 2000;  19 3799-3804
    CrossrefPubMedGoogle Scholar
  • 102 Wang L, Bhargava R, Zheng T et al.. Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of the novel EWS-SP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions.  J Mol Diagn. 2007;  9 498-509
    CrossrefPubMedGoogle Scholar
  • 103 Ng T L, O'Sullivan M J, Pallen C J et al.. Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV.  J Mol Diagn. 2007;  9 459-463
    CrossrefPubMedGoogle Scholar
  • 104 Shing D C, McMullan D J, Roberts P et al.. FUS/ERG gene fusions in Ewing's tumors.  Cancer Res. 2003;  63 4568-4576
    PubMedGoogle Scholar
  • 105 Douglass E C, Rowe S T, Valentine M et al.. A second nonrandom translocation, der(16)t(1;16)(q21;q13), in Ewing sarcoma and peripheral neuroectodermal tumor.  Cytogenet Cell Genet. 1990;  53 87-90
    PubMedGoogle Scholar
  • 106 Ladanyi M, Gerald W L. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor.  Cancer Res. 1994;  54 2837-2840
    PubMedGoogle Scholar
  • 107 Gerald W L, Rosai J, Ladanyi M. Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor.  Proc Natl Acad Sci U S A. 1995;  14 1028-1032
    PubMedGoogle Scholar
  • 108 Gerald W L, Ladanyi M, de Alava E et al.. Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small-round-cell tumor and its variants.  J Clin Oncol. 1998;  16 3028-3036
    CrossrefPubMedGoogle Scholar
  • 109 Wolf A N, Ladanyi M, Paull G et al.. The expending clinical spectrum of desmoplastic small round-cell tumor: a report of two cases with molecular confirmation.  Hum Pathol. 1999;  30 430-435
    CrossrefPubMedGoogle Scholar
  • 110 Nishio J, Iwasaki H, Ishiguro M et al.. Intra-abdominal small round cell tumour with EWS-WT1 fusion transcript in an elderly patient.  Histopathology. 2003;  42 410-412
    CrossrefPubMedGoogle Scholar
  • 111 Benjamin L E, Fredericks W J, Barr F G et al.. Fusion of the EWS1 and WT1 genes as a result of the t(11;22)(p13;q12) translocation in desmoplastic small round cell tumors.  Med Pediatr Oncol. 1996;  27 434-439
    CrossrefPubMedGoogle Scholar
  • 112 Tison V, Cerasoli S, Morigi F et al.. Intracranial desmoplastic small-cell tumor: report of a case.  Am J Surg Pathol. 1996;  20 112-117
    CrossrefPubMedGoogle Scholar
  • 113 Barr F G, Galili N, Holick J et al.. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma.  Nat Genet. 1993;  3 113-117
    CrossrefPubMedGoogle Scholar
  • 114 Galili N, Davis R J, Fredericks W J et al.. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma.  Nat Genet. 1993;  5 230-235
    CrossrefPubMedGoogle Scholar
  • 115 Davis R J, D'Cruz C M, Lovell M A et al.. Fusion of PAX7 to FKHR by the variant t(1;3)(p36;q14) translocation in alveolar rhabdomyosarcoma.  Cancer Res. 1994;  54 2869-2872
    PubMedGoogle Scholar
  • 116 Barr F G. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.  Oncogene. 2001;  20 5736-5746
    CrossrefPubMedGoogle Scholar
  • 117 Crew A J, Clark J, Fisher C et al.. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma.  EMBO J. 1995;  14 2333-2340
    PubMedGoogle Scholar
  • 118 Fligman I, Lonardo F, Jhanwar S C et al.. Molecular diagnosis of synovial sarcoma and characterization of a variant SYT-SSX2 fusion transcript.  Am J Pathol. 1995;  147 1592-1599
    PubMedGoogle Scholar
  • 119 Skytting B, Nilsson G, Brodin B et al.. A novel fusion gene, SYT-SSX4, in synovial sarcoma.  J Natl Cancer Inst. 1999;  91 974-975
    CrossrefPubMedGoogle Scholar
  • 120 Mancuso T, Mezzelani A, Riva C et al.. Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma.  Lab Invest. 2000;  80 805-813
    PubMedGoogle Scholar
  • 121 Panagopoulos I, Höglund M, Mertens F et al.. Fusion of EWS and CHOP genes in myxoid liposarcoma.  Oncogene. 1996;  12 489-494
    PubMedGoogle Scholar
  • 122 Crozat A, Åman P, Mandahl N et al.. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma.  Nature. 1993;  363 640-644
    CrossrefPubMedGoogle Scholar
  • 123 Rabbitts T H, Forster A, Larson R et al.. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma.  Nat Genet. 1993;  4 175-180
    CrossrefPubMedGoogle Scholar
  • 124 Dal-Cin P, Sciot R, Panagopoulos I et al.. Additional evidence of a variant translocation t(12;22) with EWS/CHOP fusion in myxoid liposarcoma: clinicopathological features.  J Pathol. 1997;  182 437-441
    PubMedGoogle Scholar
  • 125 Joyama S, Ueda T, Shimizu K et al.. Chromosome rearrangement at 17q25 and Xp11.2 in alveolar soft-part sarcoma: a case reported and review of the literature.  Cancer. 1999;  86 1246-1250
    CrossrefPubMedGoogle Scholar
  • 126 Ladanyi M, Lui M Y, Antonescu C R et al.. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25.  Oncogene. 2001;  20 48-57
    CrossrefPubMedGoogle Scholar
  • 127 Zucman J, Delattre O, Desmaze C et al.. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts.  Nat Genet. 1993;  4 341-345
    CrossrefPubMedGoogle Scholar
  • 128 Panagopoulos I, Mertens F, Debiec-Rychter M et al.. Molecular genetic characterization of the EWS/ATF1 fusion gene in clear cell sarcoma of tendons and aponeuroses.  Int J Cancer. 2002;  99 560-567
    CrossrefPubMedGoogle Scholar
  • 129 Speleman F, Delattre O, Peter M et al.. Malignant melanoma of the soft parts (clear-cell sarcoma): conformation of EWS and ATF-1 gene fusion caused by a t(11;22) translocation.  Mod Pathol. 1997;  10 496-499
    PubMedGoogle Scholar
  • 130 Antonescu C R, Tschernyavsky S J, Woodruff J M et al.. Molecular diagnosis of clear cell sarcoma: detection of EWS-ATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases.  J Mol Diagn. 2002;  4 44-52
    PubMedGoogle Scholar
  • 131 Covinsky M, Gong S, Rajaram V et al.. EWS-ATF1 fusion transcripts in gastrointestinal tumors previously diagnosed as malignant melanoma.  Hum Pathol. 2005;  36 74-81
    CrossrefPubMedGoogle Scholar
  • 132 Antonescu C R, Nafa K, Segal N H et al.. EWS-CREB1: a recurrent variant fusion in clear cell sarcoma-association with gastrointestinal location and absence of melanocytic differentiation.  Clin Cancer Res. 2006;  12 5356-5362
    CrossrefPubMedGoogle Scholar
  • 133 Heim S, Mietelman F. Cancer Cytogenetics. Chromosomal and Molecular Genetic Aberrations of Tumor Cells. New York; Wiley-Liss 1995
    Google Scholar
  • 134 Lasota J. Genetics of soft tissue tumors. In: Miettinen M Diagnostic Soft Tissue Pathology. Philadelphia; Churchill Livingstone 2003: 99-142
    Google Scholar
  • 135 Pfeifer J D. Molecular Genetic Testing In Surgical Pathology. Philadelphia; Lippincott Williams & Wilkins 2006
    Google Scholar
  • 136 Kohl N E, Kanda N, Schreck R R et al.. Transposition and amplification of oncogene-related sequences in human neuroblastomas.  Cell. 1983;  35 359-367
    CrossrefPubMedGoogle Scholar
  • 137 Schwab M, Varmus H E, Bishop J M et al.. Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc.  Nature. 1984;  308 288-291
    CrossrefPubMedGoogle Scholar
  • 138 Brodeur G M, Seeger R C, Schwab M et al.. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.  Science. 1984;  224 1121-1124
    CrossrefPubMedGoogle Scholar
  • 139 Seeger R C, Brodeur G M, Sather H et al.. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.  N Engl J Med. 1985;  313 1111-1116
    CrossrefPubMedGoogle Scholar
  • 140 Brodeur G M, Azar C, Brother M et al.. Neuroblastoma: effect of genetic factors on prognosis and treatment.  Cancer. 1992;  70 1685-1694
    PubMedGoogle Scholar
  • 141 Wolf M, Aaltonen L A, Szymanska J et al.. Complexity of 12q13-22 amplicon in liposarcoma: microsatellite repeat analysis.  Genes Chromosomes Cancer. 1997;  18 66-70
    CrossrefPubMedGoogle Scholar
  • 142 Berner J M, Forus A, Elkahloun A et al.. Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas.  Genes Chromosomes Cancer. 1996;  17 254-259
    CrossrefPubMedGoogle Scholar
  • 143 Elkahloun A G, Bittner M, Hoskins K et al.. Molecular cytogenetic characterization and physical mapping of 12q13-15 amplification in human cancer.  Genes Chromosomes Cancer. 1996;  17 205-214
    CrossrefPubMedGoogle Scholar
  • 144 Reifenberger G, Ichimura K, Reinferberger G et al.. Refined mapping of 12q13-15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets.  Cancer Res. 1996;  56 5141-5145
    PubMedGoogle Scholar
  • 145 Fakharzadeh S S, Trusko S P, George D L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.  EMBO J. 1991;  10 1565-1569
    PubMedGoogle Scholar
  • 146 Kussie P H, Gorina S, Marechal V et al.. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.  Science. 1996;  274 948-953
    CrossrefPubMedGoogle Scholar
  • 147 Buschmann T, Fuchs S Y, Lee C G et al.. SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53.  Cell. 2000;  101 753-762
    CrossrefPubMedGoogle Scholar
  • 148 Xiao Z X, Chen J, Levine A J et al.. Interaction between the retinoblastoma protein and the oncoprotein MDM2.  Nature. 1995;  375 694-698
    CrossrefPubMedGoogle Scholar
  • 149 Kanoe H, Nakayama T, Murakami H et al.. Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation.  Anticancer Res. 1998;  18 2317-2321
    PubMedGoogle Scholar
  • 150 Nakayama T, Toguchida J, Wadayama B et al.. MDM2 gene amplification in bone and soft tissue tumors: association with tumor progression in differentiated adipose tissue tumors.  Int J Cancer. 1995;  64 342-346
    CrossrefPubMedGoogle Scholar
  • 151 Pedeutour F, Forus A, Coindre J M et al.. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors.  Genes Chromosomes Cancer. 1999;  24 30-41
    CrossrefPubMedGoogle Scholar
  • 152 Suijkerbuijk R F, Olde Weghuis D E, Van den Berg M et al.. Comparative genomic hybridization as a tool to define two distinct chromosome 12-derived amplification units in well differentiated liposarcomas.  Genes Chromosomes Cancer. 1994;  9 292-295
    CrossrefPubMedGoogle Scholar
  • 153 Szymanska J, Virolainen M, Tarkkanen M et al.. Overrepresentation of 1q21-23 and 12q13-21 in lipoma-like liposarcomas but not in benign lipomas: a comparative genomic hybridization study.  Cancer Genet Cytogenet. 1997;  99 14-18
    CrossrefPubMedGoogle Scholar
  • 154 Pilotti S, Della Torre G, Lavarino C et al.. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implication for different pathogenetic mechanisms.  J Pathol. 1997;  181 14-24
    PubMedGoogle Scholar
  • 155 Miettinen M Gastrointestinal stromal tumors. Semin Diagn Pathol 2006 23: 61-129
    Google Scholar
  • 156 Cohen Jr M M, Howell R E. Etiology of fibrous dysplasia and McCune-Albright syndrome.  Int J Oral Maxillofac Surg. 1999;  28 366-371
    CrossrefPubMedGoogle Scholar
  • 157 Knudson A G. Mutation and cancer: statistical study of retinoblastoma.  Proc Natl Acad Sci U S A. 1971;  68 820-823
    CrossrefPubMedGoogle Scholar
  • 158 Kinzler K W, Nilbert M C, Su L-K et al.. Identification of FAP locus genes from chromosome 5q21.  Science. 1991;  253 661-665
    CrossrefPubMedGoogle Scholar
  • 159 Nishisho I, Nakamura Y, Miyoshi Y et al.. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients.  Science. 1991;  253 665-669
    CrossrefPubMedGoogle Scholar
  • 160 Groden J, Thliveris A, Samowitz W et al.. Identification and characterization of the familial adenomatous polyposis coli gene.  Cell. 1991;  66 589-600
    CrossrefPubMedGoogle Scholar
  • 161 Joslyn G, Carlson M, Thliveris A et al.. Identification of deletion mutation and three new genes at the familial polyposis locus.  Cell. 1991;  66 601-613
    CrossrefPubMedGoogle Scholar
  • 162 Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives.  Biochim Biophys Acta. 1998;  1378 F115-F177
    PubMedGoogle Scholar
  • 163 Orlow I, Drobnjak M, Zhang Z F et al.. Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival.  J Natl Cancer Inst. 1999;  91 73-79
    CrossrefPubMedGoogle Scholar
  • 164 Hussussian C J, Struewing J P, Goldstein A M et al.. Germline p16 mutations in familial melanoma.  Nat Genet. 1994;  8 15-21
    PubMedGoogle Scholar
  • 165 Greene M H. The genetics of hereditary melanoma and nevi. 1998 update.  Cancer. 1999;  86 2464-2477
    CrossrefPubMedGoogle Scholar
  • 166 Knudson A G. Mutation and cancer: statistical study of retinoblastoma.  Proc Natl Acad Sci U S A. 1971;  68 820-823
    CrossrefPubMedGoogle Scholar
  • 167 Horowitz J M, Yandell D W, Park S-H et al.. Point mutational inactivation of the retinoblastoma antioncogene.  Science. 1989;  243 937-940
    CrossrefPubMedGoogle Scholar
  • 168 Lohmann D R. RB1 gene mutations in retinoblastoma.  Hum Mutat. 1999;  14 283-288
    CrossrefPubMedGoogle Scholar
  • 169 Cohen J A, Geradts J. Loss of RB and MTS1/CDKN2 (p16) expression in human sarcomas.  Hum Pathol. 1997;  28 893-898
    CrossrefPubMedGoogle Scholar
  • 170 Orkin S H, Goldman D S, Sallan S E. Development of homozygosity for chromosome 11p markers in Wilms' tumour.  Nature. 1984;  309 172-174
    CrossrefPubMedGoogle Scholar
  • 171 Weissman B E, Saxon P J, Pasquale S R et al.. Introduction of normal human chromosome into Wilms' tumor cell line controls its tumorigenic expression.  Science. 1987;  236 175-180
    CrossrefPubMedGoogle Scholar
  • 172 Kumar-Singh S, Segers K, Rodeck U et al.. WT1 mutations in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.  J Pathol. 1997;  181 67-74
    PubMedGoogle Scholar
  • 173 Barbaux S, Niaudet P, Gubler M C et al.. Donor splice-site mutations in WT1 are responsible for Frasier syndrome.  Nat Genet. 1997;  17 467-470
    CrossrefPubMedGoogle Scholar
  • 174 Pelletier J, Bruening W, Kashtan C E et al.. Germinal mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome.  Cell. 1991;  67 437-447
    CrossrefPubMedGoogle Scholar
  • 175 Malkin D, Li F P, Strong L C et al.. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.  Science. 1990;  250 1233-1238
    CrossrefPubMedGoogle Scholar
  • 176 Varley J M, Evans D GR, Birch J M. Li-Fraumeni syndrome-a molecular and clinical review.  Br J Cancer. 1997;  76 1-14
    PubMedGoogle Scholar
  • 177 Rasmussen S A, Friedman J M. NF1 gene and neurofibromatosis 1.  Am J Epidemiol. 2000;  151 33-40
    CrossrefPubMedGoogle Scholar
  • 178 Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP.  Cell. 2001;  104 593-604
    CrossrefPubMedGoogle Scholar
  • 179 Colman S D, Williams C A, Wallace R W. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene.  Nat Genet. 1995;  11 90-92
    PubMedGoogle Scholar
  • 180 Lothe R A, Slettan A, Saeter G et al.. Alterations at chromosome 17 loci in peripheral nerve sheath tumors.  J Neuropathol Exp Neurol. 1995;  54 65-73
    PubMedGoogle Scholar
  • 181 Gutmann D H. Molecular insights into neurofibromatosis 2.  Neurobiol Dis. 1997;  3 247-261
    CrossrefPubMedGoogle Scholar
  • 182 Merel P, Hoang-Xuan K, Sanson M et al.. Screening for germ-line mutations in the NF2 gene.  Genes Chromosomes Cancer. 1995;  12 117-127
    CrossrefPubMedGoogle Scholar
  • 183 Bianchi A B, Mitsunaga S I, Cheng J Q et al.. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.  Proc Natl Acad Sci U S A. 1995;  92 10854-10858
    CrossrefPubMedGoogle Scholar
  • 184 Bijlsma E K, Merel P, Bosch D A et al.. Analysis of mutations in the SCH gene in schwannomas.  Genes Chromosomes Cancer. 1994;  11 7-14
    CrossrefPubMedGoogle Scholar
  • 185 Lasota J, Fetsch J F, Wozniak A et al.. The neurofibromatosis type 2 gene is mutated in perineural cell tumors. A molecular genetic study of eight cases.  Am J Pathol. 2001;  158 1223-1229
    PubMedGoogle Scholar
  • 186 Biegel J A, Rorke L B, Packer R J et al.. Monosomy 22 in rhabdoid or atypical tumors of the brain.  J Neurosurg. 1990;  73 710-714
    PubMedGoogle Scholar
  • 187 Biegel J A, Burk C D, Parmiter A H et al.. Molecular analysis of partial deletion of 22q in a central nervous system rhabdoid tumor.  Genes Chromosomes Cancer. 1992;  5 104-108
    CrossrefPubMedGoogle Scholar
  • 188 Biegel J A, Allen C S, Kawasaki K et al.. Narrowing the critical region for the rhabdoid tumor locus in 22q11.  Genes Chromosomes Cancer. 1996;  16 94-105
    CrossrefPubMedGoogle Scholar
  • 189 Versteege I, Sevenet N, Lange J et al.. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.  Nature. 1998;  394 203-206
    CrossrefPubMedGoogle Scholar
  • 190 Fletcher CD, Unni KK, Mertens F Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon; IARC Press 2002
    Google Scholar
  • 191 Cremer T, Lichter P, Borden J et al.. Detection of chromosome aberrations in metaphase and interphase tumor cells by in situ hybridization using chromosome-specific library probes.  Hum Genet. 1988;  80 235-246
    PubMedGoogle Scholar
  • 192 Pinkel D, Straume T, Gray J W. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization.  Proc Natl Acad Sci U S A. 1986;  83(9) 2934-2938
    PubMedGoogle Scholar
  • 193 Cohen N, Betts D R, Trakhtenbrot L et al.. Detection of unidentified chromosome abnormalities in human neuroblastoma by spectral karyotyping (SKY).  Genes Chromosomes Cancer. 2001;  31 201-208
    CrossrefPubMedGoogle Scholar
  • 194 Mrozek K, Iliszko M, Rys J et al.. Spectral karyotyping reveals 17;22 fusions in a cytogenetically atypical dermatofibrosarcoma protuberans with a large marker chromosome as a sole abnormality.  Genes Chromosomes Cancer. 2001;  31 182-186
    CrossrefPubMedGoogle Scholar
  • 195 Mullis K B, Faloona F. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction.  Methods Enzymol. 1987;  155 335-350
    PubMedGoogle Scholar
  • 196 Erlich H A. PCR Technology. Principles and Applications for DNA Amplification. New York; Stockton Press 1989
    Google Scholar
  • 197 McPherson MJ, Quirke P, Taylor GR PCR. A Practical Approach. New York; Oxford University Press 1992
    Google Scholar
  • 198 Downing J R, Khandekar A, Shurtleff S A et al.. Multiplex RT-PCR assay for the differential diagnosis of alveolar rhabdomyosarcoma and Ewing's sarcoma.  Am J Pathol. 1995;  146 626-634
    PubMedGoogle Scholar
  • 199 Lasota J, Miettinen M. Absence of Kaposi's sarcoma-associated virus (human herpesvirus-8) sequences in angiosarcoma.  Virchows Arch. 1999;  434 51-56
    CrossrefPubMedGoogle Scholar
  • 200 Livak K J, Flood S J, Marmaro J et al.. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization.  PCR Methods Appl. 1995;  4 357-362
    PubMedGoogle Scholar
  • 201 Peter M, Gilbert E, Delattre O. A multiplex real-time PCR assay for the detection of gene fusions observed in solid tumors.  Lab Invest. 2001;  81 905-912
    PubMedGoogle Scholar
  • 202 Bijwaard K E, Fetsch J F, Przygodzki R et al.. Detection of SYT-SSX fusion transcripts in archival synovial sarcomas by real time reverse transcriptase-polymerase chain reaction.  J Mol Diagn. 2002;  4 59-64
    PubMedGoogle Scholar
  • 203 Joensuu H, Roberts P J, Sarlomo-Rikala M et al.. Effect of tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.  N Engl J Med. 2001;  344 1052-1056
    CrossrefPubMedGoogle Scholar
  • 204 Demetri G D. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).  Eur J Cancer. 2002;  38 S52-S59
    PubMedGoogle Scholar
  • 205 Van Glabbeke M, Verweij J, Casali P G et al.. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organization for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.  J Clin Oncol. 2005;  23 5795-5804
    CrossrefPubMedGoogle Scholar
  • 206 Heinrich M C, Corless C L, Demetri G D et al.. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.  J Clin Oncol. 2003;  21 4342-4349
    PubMedGoogle Scholar
  • 207 Debiec-Rychter M, Sciot R, Le Cesne A et al.. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumors.  Eur J Cancer. 2006;  42 1093-1103
    CrossrefPubMedGoogle Scholar
  • 208 Antonescu C R, Besmer P, Guo T et al.. Acquired resistance to imatinib in gastrointestinal stromal tumors occurs through secondary gene mutation.  Clin Cancer Res. 2005;  11 4182-4190
    CrossrefPubMedGoogle Scholar
  • 209 Chen L L, Trent J C, Wu E F et al.. A missense mutation in KIT domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.  Cancer Res. 2004;  64 5913-5919
    PubMedGoogle Scholar
  • 210 Debiec-Rychter M, Cools J, Dumez H et al.. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.  Gastroenterology. 2005;  128 270-279
    CrossrefPubMedGoogle Scholar
  • 211 Tamborini E, Bonadiman L, Greco A et al.. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.  Gastroenterology. 2004;  127 294-299
    CrossrefPubMedGoogle Scholar
  • 212 McLean S R, Gana-Weisz M, Hartzoulakis B et al.. Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala.  Mol Cancer Ther. 2005;  4 2008-2015
    CrossrefPubMedGoogle Scholar
  • 213 Heinrich M C, Corless C L, Blanke C D et al.. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.  J Clin Oncol. 2006;  24 4764-4774
    CrossrefPubMedGoogle Scholar
  • 214 Faivre S, Delbaldo C, Vera K et al.. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.  J Clin Oncol. 2006;  24 25-35
    CrossrefPubMedGoogle Scholar
  • 215 Joensuu H. Second line therapies for the treatment of gastrointestinal stromal tumor.  Curr Opin Oncol. 2007;  19 353-358
    CrossrefPubMedGoogle Scholar
  • 216 Maki R G. Recent advances in therapy for gastrointestinal stromal tumors.  Curr Oncol Rep. 2007;  9 165-169
    CrossrefPubMedGoogle Scholar
  • 217 Heinrich M C, Corless C L, Liegl B et al.. Mechanisms of sunitinib malate (SU) resistance in gastrointestinal stromal tumors (GISTs). J Clin Oncol 2007 2007 ASCO Annual Meeting Proceedings Part I. 25 No.18S 10006
    Google Scholar

Jerzy LasotaM.D. 

Department of Soft Tissue and Orthopedic Pathology, Armed Forces Institute of Pathology

6825 16th St., N.W., Bldg. 54, Washington, DC 20306-6000

Email: lasota@afip.osd.mil